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Abstract: Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is
a dNTP triphosphohydrolase involved in the regulation of the intracellular dNTP pool, linked to
viral restriction, cancer development and autoimmune disorders. SAMHD1 function is regulated by
phosphorylation through a mechanism controlled by cyclin-dependent kinases and tightly linked
to cell cycle progression. Recently, SAMHD1 has been shown to decrease the efficacy of nucleotide
analogs used as chemotherapeutic drugs. Here, we demonstrate that SAMHD1 can enhance or
decrease the efficacy of various classes of anticancer drug, including nucleotide analogues, but also
anti-folate drugs and CDK inhibitors. Importantly, we show that selective CDK4/6 inhibitors are
pharmacological activators of SAMHD1 that act by inhibiting its inactivation by phosphorylation.
Combinations of a CDK4/6 inhibitor with nucleoside or folate antimetabolites potently enhanced
drug efficacy, resulting in highly synergic drug combinations (CI < 0.04). Mechanistic analyses reveal
that cell cycle-controlled modulation of SAMHD1 function is the central process explaining changes
in anticancer drug efficacy, therefore providing functional proof of the potential of CDK4/6 inhibitors
as a new class of adjuvants to boost chemotherapeutic regimens. The evaluation of SAMHD1
expression in cancer tissues allowed for the identification of cancer types that would benefit from
the pharmacological modulation of SAMHD1 function. In conclusion, these results indicate that the
modulation of SAMHD1 function may represent a promising strategy for the improvement of current
antimetabolite-based treatments.
Keywords: SAMHD1; antimetabolite; CDK4/6; pemetrexed; HIV; cancer
1. Introduction
Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is a
deoxynucleotide triphosphate hydrolase [1]. Through its dNTPase activity, SAMHD1 maintains
the intracellular dNTP pool at levels adequate for DNA replication and repair but below a
potentially mutagenic threshold [2]. Mutations in SAMHD1 were first identified as being causative of
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Aicardi–Goutieres syndrome (AGS), a severe autoimmune disease [3], but later it was proposed as a
tumor suppressor gene, since mutations in SAMHD1 are associated with different types of cancer [4,5]
and its expression has been found to be inhibited in several types of tumors [6,7]. More recently,
SAMHD1 has been implicated in the protection against cancer and chronic inflammation by limiting
the release of single-stranded DNA [8].
SAMHD1 also acts as a viral restriction factor, limiting the permissiveness of cells to diverse
viruses (reviewed in [9]), including human immunodeficiency virus (HIV-1) [10,11]. SAMHD1
inhibits retroviral replication at the reverse transcription (RT) step by maintaining the intracellular
concentration of dNTP below the threshold required for reverse transcription of the viral RNA genome
into DNA [10,11]. SAMHD1 activity is counteracted by the HIV-2 accessory protein Vpx, a tool that has
been extensively used to study SAMHD1 function [10,12]. In addition, SAMHD1 function is inhibited
by phosphorylation, a process controlled by cyclin-dependent kinases (CDK) and therefore tightly
regulated during cell cycle progression [13–15]. Different pharmacological agents have been shown to
block SAMHD1 phosphorylation, inducing SAMHD1 function and viral restriction [16–20].
Nucleoside analogues are commonly used in the treatment of viral infections and cancer [21].
Following phosphorylation by intracellular kinases, these analogues are structurally similarly to
endogenous dNTP. SAMHD1 has been shown to affect the efficacy of nucleoside analogs, either used
as antiretrovirals [22–26] or as chemotherapeutic drugs [27–29]. Active SAMHD1 catalyzes the
hydrolysis and inactivation of a number of different nucleoside analogues [30,31], including cytarabine
(Cytosar-U®,Ara-C), a first line therapeutic agent for acute myelogenous leukaemia (AML) and
SAMHD1 expression levels were negatively correlated with Ara-C treatment success in individuals
with AML [27,29,32].
Here, we evaluated how SAMHD1 function modifies the efficacy of a wide range of nucleoside
and non-nucleoside antimetabolites currently used to treat cancer. We show that SAMHD1 can either
enhance or limit the efficacy of a number of chemotherapeutic drugs, allowing us to discern between
those acting as enzyme substrates or competitors. Importantly, we identify anti-folate drugs as being
affected by SAMHD1 expression and function. Moreover, pharmacological activation of SAMHD1 by
highly selective CDK4/6 inhibitors significantly enhanced the efficacy of drugs acting as competitors.
Thus, pharmacological modulation of SAMHD1 activity has the potential to improve antiviral and
anti-cancer therapies and paves the way to the identification of malignancies that may be treated with
new drug combinations.
2. Results
2.1. SAMHD1 Regulates Antiviral Efficacy of Antimetabolites in Primary Cells
Primary monocyte-derived macrophages (MDMs) are susceptible to HIV-1 infection, and its
replication capacity is dependent on SAMHD1 expression. Additionally, M-CSF-induced differentiation
initiates MDM proliferation accompanied by SAMHD1 phosphorylation. Thus, HIV-1 infection of
MDM provides an excellent model in which to test the activity of antimetabolite drug efficacy.
Anti-HIV-1 activity of a panel of antimetabolite drugs used in cancer treatment was evaluated in
MDMs in the presence or absence of SAMHD1, after transducing cells with HIV-2 Vpx (Figure 1A).
As previously observed, Vpx-mediated degradation of SAMHD1 reduced the antiviral potency of the
nucleoside reverse transcriptase inhibitor (NRTI) AZT compared to untreated macrophages, but did
not change the activity of NVP, a non-nucleoside reverse transcriptase inhibitor (NNRTI) (Figure 1B).
Conversely, degradation of SAMHD1 improved the anti-HIV-1 potency of AraC in MDM (Figure 1C).
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Figure 1. (A) Degradation of sterile alpha motif and histidine-aspartic acid domain-containing protein 
1 (SAMHD1) by HIV-2 Vpx enhances HIV-1 replication in monocyte-derived macrophages (MDMs). 
MDMs previously treated or not with HIV-2 Vpx were infected with a VSV-pseudotyped HIV-1 GFP 
virus and replication assessed 2 days later by measuring GFP expression. A 5-fold change in HIV-1 
replication was observed after Vpx-mediated SAMHD1 degradation. Mean ±SD of ten independent 
donors performed in duplicate is shown. A representative western blot showing degradation of 
SAMHD1 expression in MDMs after Vpx treatment is also shown. (B) Decreased sensitivity of AZT 
after Vpx-mediated SAMHD1 degradation in MDMs. Dose response of the NRTI AZT and NNRTIs 
NVP, in wild-type (■) or SAMHD1-depleted (Δ) MDMs. Inhibition of HIV infection was measured as 
the percentage of GFP+ cells relative to the no drug condition. Mean ±SD of at least ten independent 
donors performed in duplicate is shown. (C) SAMHD1 modifies antiviral activity of AraC. Dose 
response of the AraC in wild-type (■) or SAMHD1-depleted (Δ) MDM. Inhibition of HIV infection 
was measured as the percentage of GFP+ cells relative to the no drug condition. Mean ±SD of at least 
three independent donors performed in duplicate is shown. Mean ±SD of at least three independent 
experiments performed in triplicate is shown. *p < 0.05; ** p < 0.005; *** p < 0.0005. 
Next, we tested the antiviral activity of a panel of antimetabolites currently used in cancer 
treatments in wild type or SAMHD1 depleted macrophages. All evaluated drugs inhibited HIV-1 
replication, although with different potency (Table 1). SAMHD1 expression effectively modified the 
antiviral activity of all antimetabolites tested. However, and in contrast with previous reports, 
SAMHD1 degradation either enhanced (cladribine, clofarabine, and nelarabine) or decreased 
(capecitabine, floxuridine and fluorouracil) the potency of the nucleoside analogues tested (Figure 
2A). Of note, SAMHD1 degradation dramatically impaired the efficacy of anti-folate inhibitors such 
as pemetrexed and methotrexate (Figure 2B). Calculation of 50% effective concentrations (EC50) of 
antimetabolites in macrophages expressing SAMHD1 or not showed over 30-fold and 100-fold 
increases in drugs showing enhanced or diminished potency in SAMHD1-depleted cells, respectively 
(Table 1). The enhanced or decreased efficacy of the compounds tested was not dependent on the 
nature of the specific nucleotide targeted, i.e., purine or pyrimidine, and was not limited to 
Figure 1. (A) Degradation of sterile alpha motif and histidine-aspartic acid domain-containing protein
1 (SAMHD1) by HIV-2 Vpx enhances HIV-1 replication in monocyte-derived macrophages (MDMs).
MDMs previously treated or not with HIV-2 Vpx were infected with a VSV-pseudotyped HIV-1 GFP
virus and replication assessed 2 days later by measuring GFP expression. A 5-fold change in HIV-1
replication was observed after Vpx-mediated SAMHD1 degradation. Mean ±SD of ten independent
donors performed in duplicate is shown. A representative western blot showing degradation of
SAMHD1 expression in MDMs after Vpx treatment is also shown. (B) Decreased sensitivity of
AZT after Vpx-mediated SAMHD1 degradation in MDMs. Dose response of the NRTI AZT and
NNRTIs NVP, in wild-type () or SAMHD1-depleted (∆) MDMs. Inhibition of HIV infection was
measured as the percentage of GFP+ cells relative to the no drug condition. Mean ±SD of at least ten
independent donors performed in duplicate is shown. (C) SAMHD1 modifies antiviral activity of
AraC. Dose response of the AraC in wild-type () or SAMHD1-depleted (∆) MDM. Inhibition of HIV
infection was measured as the percentage of GFP+ cells relative to the no drug condition. Mean ±SD
of at least three independent donors performed in duplicate is shown. Mean ±SD of at least three
independent experiments perfor ed in triplicate is shown. * p < 0.05; ** p < 0.005; *** p < 0.0005.
Next, we tested the antiviral activity of a panel of antimetabolites currently used in cancer
treatm nts in wild type or SAMHD1 depleted m crophages. All evaluated drugs inhibited HIV-1
replication, although with different pot ncy (Table 1). SAMHD1 expression effectively modified the
antiviral activity of all an imetabolites tested. However, and in contrast with pr vious r ports, SAMHD1
degradation either enhanced (cladr bine, clofarabin , and elarabine) or decreased (capecitabine,
floxuridine and fluorouracil) the potency of the nucleoside nalogues tested (Figure 2A). Of note,
SAMHD1 d gradation dramatically impaired the efficacy of anti-folate inhibitors s ch as pemetrexed
and methotrexate (Figure 2B). Calculation of 50% effectiv concentrations (EC50) of antimetabolites in
macrophages expressing SAMHD1 or not showed over 30-fold and 100-fold in reases in drugs showing
e hanced or diminished potency in SAMHD1-depleted cells, respectively (Table 1). The enhanced or
decreased efficacy of the compounds tested was not dep dent on the natur of the specific nucleotide
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targeted, i.e., purine or pyrimidine, and was not limited to nucleos(t)ide analogues, as SAMHD1 also
affected the efficacy of anti-folate drugs such as pemetrexed and methotrexate (Table 1).
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Figure 2. SAMHD1 modifies antiviral and activity of antimetabolites. Dose response of the nucleoside
analogues (A) or anti-folate drugs (B) currently used as anti-cancer treatments in wild-type () or
SAMHD1-depleted (∆) MDMs. Inhibition of HIV infection was measured as the percentage of GFP+
cells relative to the no drug condition. Mean ±SD of at least three independent donors performed in
duplicate is shown. * p < 0.05; ** p < 0.005; *** p < 0.0005.
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Table 1. Anti-HIV-1 activity of antimetabolites (AraC, fludarabine, nelarabine, cladribine, clofarabine,
gemcitabine, floxuridine, fluorouracil, pemetrexed and methotrexate) and antiretrovirals (AZT and
NVP) in macrophages expressing or not SAMHD1. The values of EC50 were calculated in primary
MDMs untreated or transduced with HIV-2 Vpx that led to SAMHD1 degradation.
Drugs Drug Type (Base Targeted) EC50 (µM) FC
SAMHD1 (+) SAMHD1 (-) -/+ +/-
AZT NRTI (dT) 0.006 0.11 18 -
NVP NNRTI (none) 0.88 0.95 1 1
AraC Pyrimidine (dC) 3.24 0.11 - 30
Nelarabine Purine (dG) 13.96 1.83 - 8
Cladribine Purine (dA) 0.029 0.007 - 4
Clofarabine Purine (dG) 0.034 0.006 - 6
Floxuridine Pyrimidine (dU) 0.73 20.28 28 -
Fluorouracil Pyrimidine (dU) 2.40 >25 >10 -
Pemetrexed Anti-folate 0.25 >25 >100 -
Methotrexate Anti-folate 0.42 79.24 190 -
EC50; Effective concentration required to block HIV-1 replication by 50%, FC; fold change or ratio of the EC50 without
SAMHD1 and the EC50 with SAMHD1 (-/+), or inversely (+/-).
2.2. SAMHD1 Is Required for Antiviral Activity of CDK4/6 Inhibitors
SAMHD1 is inactivated in proliferating cells by a mechanism that requires its
phosphorylation [13–15]. SAMHD1 phosphorylation may be directly regulated by CDK1 or CDK2,
whose activity is upstream controlled by CDK6 [14]. The antiviral activity of the highly selective CDK4/6
inhibitor palbociclib is dependent on SAMHD1 expression [14,19] (Figure 3A). Thus, the efficacy of
two other specific CDK4/6 inhibitors, ribociclib and abemaciclib, was also evaluated in the presence or
absence of SAMHD1. The three agents were tested at the concentration where palbociclib showed the
highest efficacy in cell culture (1 µM, Figure 3A). As expected, the activity of all three CDK4/6 inhibitors
was lost in the absence of SAMHD1, indicating that the efficacy of CDK4/6 inhibitors depends on
SAMHD1 expression (Figure 3B). Interestingly, similar results were obtained when the multi-kinase
inhibitor midostaurin was evaluated (Figure S1A), suggesting that activity of multiple types of kinase
inhibitors may be influenced by SAMHD1 expression.
To explore the cellular and molecular determinants of SAMHD1 requirement for kinase inhibitor
function, SAMHD1 expression and phosphorylation was measured by Western blot. Both palbociclib
and midostaurin blocked SAMHD1 phosphorylation, whereas SAMHD1 protein expression was not
affected (Figure 3C, Figure S1B). In addition, we observed a concomitant dephosphorylation and
decreased expression of Rb, a substrate of CDK6, suggesting that palbociclib and midostaurin also
affect CDK6-mediated CDK2 phosphorylation of SAMHD1 (Figure 3C, Figure S1B).
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Figure 3. Antiviral efficacy of CDK4/6 inhibitors depends on SAMHD1 expression. (A) Dose response
of the CDK4/6 inhibitor Palbociclib, in wild-type () or SAMHD1-depleted (∆) MDM. Inhibition of HIV
infection was measured as the percentage of GFP+ cells relative to the no drug condition. Mean ±SD
of at least ten independent donors performed in duplicate is shown. (B) CDK4/6 inhibitors lose
antiviral activity in SAMHD1-depleted macrophages. As in (A), dose response of two other CDK4/6
inhibitors, ribociclib (left panel) and abemaciclib (right panel), in wild-type () or SAMHD1-depleted
(∆) MDMs. Mean ±SD of two independent donors performed in duplicate is shown. (C) Palbociclib
blocks SAMHD1 inactivation by phosphorylation. Western blot analysis of lysates of untreated MDMs
(no drug, ND) or macrophages treated with palbociclib at the indicated doses. Membranes were blotted
with an anti phospho-SAMHD1 antibody, total SAMHD1, anti phosho-pRB and total pRB. Hsp90
antibody was used as control. A representative donor is shown. * p < 0.05; ** p < 0.005; *** p < 0.0005.
2.3. Pharmacological Inhibition of CDK4/6 Enhances Antiviral Activity of Antimetabolites
CDK4/6 inhibitors activate SAMHD1 function through the inhibition of its phosphorylation.
Thus, we evaluated the capacity of palbociclib to modify the activity of antimetabolites. Antiviral
activity of pemetrexed and fluorouracil were evaluated alone or in combination with palbociclib in
primary macrophages.
Pemetrexed inhibited HIV-1 replication in a dose-dependent manner, although with limited
potency (EC50 = 0.1 µM, Figure 4A, black line). Combination of pemetrexed with increasing
concentrations of palbociclib (EC50 = 0.12 µM) enhanced the antiviral potency of the antimetabolite
(Figure 4A,B, left panels). The calculation of the combination index (CI) indicated strong synergy
(CI ≤ 0.041 for palbociclib at 0.04 µM combined with different concentrations of pemetrexed, Table 2).
Interestingly, pemetrexed and palbociclib activity, as well as the synergistic effect observed in drug
combinations, were lost in the absence of SAMHD1, (Figure 4A,B, right panels). Furthermore, the
combination of pemetrexed with the multi-kinase inhibitor midostaurin (EC50 = 0.62 µM) also showed
a highly synergistic effect when SAMHD1 was expressed (Figure 4C,D, left panels, Table 2), an effect
that was lost when SAMHD1 depleted cells (Figure 4C,D, right panels).
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(A) Relative effect of the combination f palbociclib-pemetrexed measured as ntiviral a tivity. Inhibition
of HIV infe tion with incr asing doses of palbociclib and pemetrexed was m asu ed. Percentage of
GFP+ cells relative to the no drug condition is shown in presence (left panel) or absence (right panel) of
SAMHD1. Mean ±SD of at least three independent donors performed in duplicate is shown. (B) As in
(A), relative effect of pemetrexed alone (white bars) or in combination with a fixed dose of palbociclib
0.04 µM (black bars), in the presence (left panel) or absence (right panel) of SAMHD1. Mean ±SD of at
least three independent donors performed in duplicate is shown. (C) Relative effect of the combination
of midostaurin-pemetrexed measured as antiviral activity. Inhibition of HIV infection with increasing
doses of midostaurin and pemetrexed was measured. Percentage of GFP+ cells relative to the no
drug condition is shown in presence (left panel) or absence (right panel) of SAMHD1. Mean ±SD
of at least three independent donors performed in duplicate is shown. (D) As in (C), relative effect
of pemetrexed (PTX) alone (white bars) or in combination with a fixed dose of midostaurin 0.2 µM
(black bars), in the presence (left panel) or absence (right panel) of SAMHD1. Mean ±SD of at least
three independent donors performed in duplicate is shown. PD, palbociclib; PTX, pemetrexed; MID,
midostaurin. * p < 0.05; ** p < 0.005; *** p < 0.0005.
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Table 2. Combination index values for pemetrexed and fluorouracil combinations with palbociclib and
midostaurin. Macrophages were treated with the different at indicated concentrations in combination
with 0.04 µM of palbociclib or 0.2 µM of midostaurin and infected with HIV-1 for 48 h. Drug efficacy
was analyzed by measuring inhibition of HIV-1 replication by flow cytometry.
Drug Combination Combination Index (CI) Effect
Pemetrexed 25 0.0049 Synergy
+ 5 0.0097 Synergy
Palbociclib 0.04 µM 1 0.0285 Synergy
0.2 0.0415 Synergy
0.04 0.0673 Synergy
Pemetrexed 25 0.079 Synergy
+ 5 0.069 Synergy
Midostaurin 0.2 µM 1 0.056 Synergy
0.2 0.045 Synergy
0.04 0.064 Synergy
Fluorouracil 5 1.871 Antagonism
+ 1 0.572 Synergy
Palbociclib 0.04 µM 0.2 0.658 Synergy
0.04 1.818 Antagonism
0.008 2.967 Antagonism
Midostaurin 5 2.074 Antagonism
+ 1 0.427 Synergy
Palbociclib 0.04 µM 0.2 0.223 Synergy
0.04 0.419 Synergy
0.008 0.324 Synergy
CI values were calculated using the mean values of three different experiments. Values were calculated using
CompuSyn software. CI < 1, synergy; CI > 1, antagonism; CI = 1, additive.
On the other hand, combination of the nucleoside analogue fluorouracil or the multikinase inhibitor
midostaurin with palbociclib showed more limited effects, i.e., palbociclib partially enhanced the
antiviral potency of fluorouracil or midostaurin in the presence of SAMHD1 (Figure S2). Combination
index calculation indicated synergy at specific concentrations, although CI were 100-fold lower
compared to palbociclib-pemetrexed drug interactions (Table 2) and antagonic or additive effects were
also seen.
Overall, these results suggest that pharmacological activation of SAMHD1 can significantly
enhance the efficacy of antimetabolites, through a mechanism that is dependent on SAMHD1 expression
and regulation.
2.4. Cytotoxic Efficacy of Antimetabolites Is Enhanced by CDK4/6 Inhibitors
Anticancer drugs are specifically designed to inhibit cell growth, thus we evaluated cytotoxic
efficacy of the antimetabolites pemetrexed and fluorouracil in combination with the CDK4/6 inhibitor
palbociblib in the TZM-bl cell line and in two distinct breast cancer cell lines, MDA-MB-468 and
T47D (Figure S3). As expected, all drugs tested resulted in decreased cell metabolic activity in all cell
lines, reflecting the number of viable cells under defined conditions. The calculation of 50% cytotoxic
concentrations (CC50) showed significant differences between them (Table S1).
The combination of pemetrexed with palbociclib enhanced the cytotoxicity of the antimetabolite
in all cell lines tested (Figure 5A–C). Importantly, the calculation of the combination index indicated a
synergistic effect in all cases, with the cytotoxic evaluation being comparable to the results obtained
when antiviral efficacy was measured (Table 3). The combination of fluorouracil with palbociclib
enhanced fluorouracil potency in TZM-bl and T47D cells but not in MDA-MB-468 cell line (Figure 5A–C,
Table 3). Interestingly, in MDA-MB-468 cells, although the expression of SAMHD1 was similar to other
lines, Rb and pRb were not detected, either at the mRNA or protein level, (Figure S3), demonstrating
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the importance of cell cycle proteins which putatively may affect SAMHD1 function in determining
palbociclib–antimetabolite drug combination efficacy.
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Figure 5. Pharmacological acti ion of SAMHD1 enhances cytotoxici y of ant metabolites. (A–C) Effect
on cell viability of palbociclib–pemetrexed combination in TZM-bl, T47D and MDA-MB-468 cell lines,
respectively. Left panels, cytotoxic activity of palbociclib alone (5 µM, white bars), pemetrexed alone
(black bars at 0.2, 1 or 0.04 µM for TZM-bl, T47D and MDA-MB-468 respectively) or the combination
of both drugs at the same concentration (grey bars). Right panels, cytotoxic activity of palbociclib
alone (5 µM, white bars), fluorouracil alone (5 µM, black bars) or the combination of both drugs at the
same concentration (grey bars). Drug concentrations were chosen depending calculated CC50 under
specific experimental conditions (Table S1). * p < 0.05; ** p < 0.005; *** p < 0.0005. PD, palbociclib; PTX,
pemetrexed; FU, 5-fluorouracil.
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Table 3. Combination index values for pemetrexed and fluorouracil combinations with palbociclib.
TZM-bl, MDA-MB-468 and T47D cells were treated with indicated concentrations of pemetrexed or
fluorouracil in combination with 5 µM of palbociclib. Cytotoxic effect of the drugs was tested by
MTT assay.
Cell Type Drug Combination Combination Index (CI) Effect
TZM-bl
Pemetrexed 1 0.806 Synergy
+ 0.2 0.689 Synergy
Palbociclib 5 µM 0.04 0.71 Synergy
0.008 0.72 Synergy
Fluorouracil 5 0.726 Synergy
+ 1 0.766 Synergy
Palbociclib 5 µM 0.2 0.764 Synergy
0.04 0.735 Synergy
T47D
Pemetrexed 5 0.783 Synergy
+ 1 0.707 Synergy
Palbociclib 5 µM 0.2 0.779 Synergy
0.04 0.874 Synergy
Fluorouracil 25 0.848 Synergy
+ 5 0.804 Synergy
Palbociclib 5 µM 1 0.966 Additive
0.2 1.01 Additive
MDA-MB-468
Pemetrexed 1 0.886 Synergy
+ 0.2 0.886 Synergy
Palbociclib 5 µM 0.04 0.921 Synergy
0.008 1.01 Additive
Fluorouracil 25 2.844 Antagonism
+ 5 1.745 Antagonism
Palbociclib 5 µM 1 1.356 Antagonism
0.2 1.125 Antagonism
CI values were calculated using the mean values of three different experiments. Values were calculated using
CompuSyn software. CI < 1, synergy; CI > 1, antagonism; CI = 1, additive.
2.5. Alternative Pathways of dNTP Metabolism Control Are Responsible for Drug Synergy
To further explore the mechanism underlying the synergistic effect observed when combining
antimetabolites with the CDK4/6 inhibitor palbociclib, protein expression in primary macrophages
treated with pemetrexed, fluorouracil and palbociclib, alone or in combination was evaluated
(Figure 6A). As expected, palbociclib alone inhibited phosphorylation of pRb and SAMHD1, therefore
activating its dNTP triphosphohydrolase function and subsequently reducing the intracellular
dNTP pool. Interestingly, pemetrexed and fluorouracil treatment resulted in different effects, i.e.,
while fluorouracil acts similarly to palbociclib, pemetrexed did not decrease the phosphorylation of
pRb and SAMHD1. Although pemetrexed activity is dependent on SAMHD1, its mechanisms of action
do not directly affect SAMHD1 phosphorylation, providing evidence for the stronger synergy observed
in the pemetrexed–palbociclib drug combination compared to fluorouracil–palbociblib.
Thus, antifolates such as pemetrexed inhibit the dNTP pool by a mechanism not directly affecting
SAMHD1 phosphorylation and effectively synergize with palbociclib, which actually induces SAMHD1
activation. On the other hand, when two compounds directly affecting SAMHD1 phosphorylation
(i.e., fluorouracil and palbociclib) are combined, the synergic effect is less potent.
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Figure 6. Regulation of dNTP pool is responsible for drug synergy. (A) Protein expression in MDMs
treated with palbociclib (PD) at 1 µM, pemetrexed (PTX) and fluorouracil (FU), both at 5µM and
the corresponding drug combinations PD+PTX and PD+FU. Hsp90 was used as a loading control.
A represe tative blot is shown. (B) Proposed model of drug interactions. Antimet bolites affe ti g
dNTP synthesis such as pemetrexed inhibit dNTP pool by a mechanism not directly affec ing SAMHD1
activation and thus synergy with anticancer drugs affecting SAMHD1 phosphorylation as palbociclib
is higher compared to compounds also targeting SAMHD1 function (i.e., fluorouracil) or exclusively
affecting SAMHD1 (i.e., midostaurin). As a consequence, the antiviral and cytotoxic efficacy of
antimetabolites is significantly enhanced when used in combination in vitro.
2.6. SAMHD1 Is Expressed in Different Tumor Tissues
To further explore the potential value of modulating SAMHD1 function in cancer patients,
we evaluated SAMHD1 expression in different tumor tissues by immunohistochemistry (IHC) in
paraffin-embedded tissues. SAMHD1 was clearly detected in at least two cancer tissue types
susceptible to being treated with antimetabolites—pancreatic adenocarcinoma and lung large cell
carcinoma (Figure 7A,B). In both cases, SAMHD1 was significantly expressed in a high percentage of
malignant cells.
In addition, IHC data of 17 different types of human tumors including 202 different samples
from human protein atlas were also analyzed (www.proteinatlas.org, [33]). Although SAMHD1 was
expressed in all types of tumors, the degree of expression was significantly variable, ranging from
undetectable levels to high protein expression levels. Overall, 70% of all tumors expressed SAMHD1 to
a certain extent, whereas its expressio could not be detected i 30% of cases (Figure 7C). These results
demonstrate that SAMHD1 is expressed in patient tumor samples but also suggest that modul tion of
SAMHD1 function might be feasible at least in a subgroup of cancer types.
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relative expression in IHC as classified in Human Proteome Atlas (www.proteinatlas.org, IHC data of
SAMHD1 expression from 17 different tumor types were retrieved and classified according to protein
expression levels. ND, not detected.
3. Discussion
Nucleotide metabolism plays a central role in cell proliferation, transformation and tumor
progression [34]. Therefore, inhibition of nucleotide synthesis has been commonly used in the treatment
of cancer, infectious diseases and immune-mediated diseases [34]. By degrading cellular dNTPs,
SAMHD1 plays an important role in the homeostatic balance of cellular dNTPs and, thus, it may
be a modulator of clinical efficacy of nucleotide-based treatments. SAMHD1 has been shown to act
as a resistance factor to nucleoside-based chemotherapies by hydrolyzing their active triphosphate
metabolite, thereby reducing the response to the anticancer drugs [28,30].
Here, we show that SAMHD1 can either enhance or limit efficacy of a wide range of antimetabolites,
including nucleoside analogues but also anti-folate drugs. Interestingly, antifolate drugs such
as pemetrexed or methotrexate showed increased potency in SAMHD1-expressing cells, whereas
nucleoside analogues efficacy was either limited or enhanced by SAMHD1. Attempts to predict the
effect of SAMHD1 on drug efficacy based on the specific base targeted or chemical structure did
not show any clear correlation, although purine nucleoside analogues may be more prone to gain
activity in SAMHD1-depleted cells. Based on previous data showing that beyond endogenous dNTPs,
triphosphorylated nucleoside analogues can be hydrolyzed by SAMHD1 [28–30,35] and considering
that recombinant SAMHD1 exhibits Ara-CTPase activity in vitro [29], we hypothesized that compounds
whose activity is enhanced in the absence of SAMHD1 are enzyme substrates. On the contrary, and as
previously demonstrated for NRTI [23–25], compounds that lose activity in the absence of SAMHD1
would be competing with the intracellular dNTP pool, which is lower when SAMHD1 is active.
Accordingly, anti-folates showed higher activity when SAMHD1 effectively limits the dNTP pool.
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As previously reported, our data indicate that SAMHD1 decreases activity of drugs used
against AML (AraC and clofarabine) and other types of hematological cancers like nelarabine for
T-lymphoblastic lymphoma, cladribine used in the treatment of hairy cell leukemia and B-cell chronic
lymphocytic leukemia, and approved for the treatment of relapsing-remitting multiple sclerosis. On the
contrary, SAMHD1 enhances the activity of drugs used to treat solid tumors, such as floxuridine,
most often used in the treatment of colorectal cancer, fluorouracil, used for colon cancer, esophageal
cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer, and anti-folate drugs,
such as methotrexate, used against a number of cancers but also to treat autoimmune diseases, such as
psoriasis, rheumatoid arthritis, and Crohn’s disease, or pemetrexed, used to treat non-small cell lung
cancer [36]. Thus, the data presented here expand the number of anticancer drugs known to be
affected by SAMHD1 function and the number of diseases that could benefit from the development of
pharmacological inhibitors or activators of SAMHD1 function.
It is known that SAMHD1 function is tightly linked to cell cycle control as its activity is regulated
by CDK-dependent phosphorylation (reviewed in [9]). We and others have identified drugs that
activate SAMHD1 function by impeding its phosphorylation [16–20]. Such drugs may be suitable for
combination therapies including antimetabolites, especially when combined with anti-folate drugs,
as synergistic effects were seen across all cell models tested. Detection of the phosphorylated form of
SAMHD1 and expression of related cell cycle proteins allowed us to suggest a mode of action where
anti-folate drugs would diminish the dNTP pool by affecting the synthesis of nucleotide precursors,
whereas CDK inhibitors deplete dNTPs by activating SAMHD1 triphosphohydrolase activity [19]
(Figure 6B). Although our data provide strong evidence of the key role of SAMHD1 in determining
efficacy of CDK4/6 inhibitors, further work will have to determine the relative contribution of SAMHD1
in each type of tumor, by, for example, performing additional evaluations in SAMHD1 in vitro and/or
in vivo knock-out models. From our data, we cannot rule out the possibility that synergy observed
in breast cancer cell lines might be not entirely dependent on SAMHD1, but due to a combination of
different factors that deserve further investigation.
Antimetabolites were the first class of cytotoxic drugs systematically tested in clinical trials that
elicited complete clinical responses as monotherapies, albeit with inevitable relapse [37]. Combination
chemotherapy still constitutes the current paradigm to achieve systemic disease control in clinical
oncology. Thus, our results might represent the first step of a novel treatment strategy directed to
the activation of SAMHD1 function. In this sense, the choice of highly selective CDK4/6 inhibitors
as the first clinically effective CDK4/6 inhibitors developed [38,39] is of special relevance. Currently,
inhibition of CDK4/6 in combination with endocrine therapies is the treatment option in hormone
receptor-positive/HER2-negative advanced breast cancer. CDK4/6 inhibitors offer an effective and
tolerable treatment that can be combined with other therapies and thus harbors therapeutic potential
for multiple cancers [40,41]. Based on our data, CDK4/6 inhibitors could boost antimetabolite-based
anticancer therapies, especially for drugs whose activity is enhanced by SAMHD1, which highlights
the need for a priori testing drug efficacy depending on SAMHD1 function.
We have applied here a screening approach based in anti-HIV-1 activity in primary macrophages
that either express SAMHD1 or do not. Our system has turned out to be a reliable and sensitive
measure of SAMHD1 drug dependency for several reasons: (i) SAMHD1 expression is easily modulated,
(ii) HIV-1 reverse transcription is a process highly sensitive to SAMHD1-mediated dNTP pool sizes
changes and can be easily monitored, (iii) cell cycle initiation and progression is not deregulated
and (iv) considers inter-individual differences by using primary cells from different donors. Indeed,
cytotoxicity data obtained in different cell lines confirmed the results from the antiviral-based screening,
except when expression of pRb was deregulated. RB is one of the key factors in cell cycle control that is
phosphorylated by activation of CDK4 and CDK6 following cell cycle entry from GO to G1 [42], as is
the case of SAMHD1.
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4. Materials and Methods
4.1. Cells
Peripheral blood mononuclear cells (PBMC) were obtained from the blood of healthy donors
using a Ficoll–Paque density gradient centrifugation and monocytes were purified using negative
selection antibody cocktails (StemCell Technologies, Vancouver, BC, Canada) as described before [43].
Monocytes were cultured in complete culture medium: RPMI 1640 medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA), penicillin
and streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) and differentiated to monocyte
derived macrophages (MDM) for 4 days in the presence of monocyte-colony stimulating factor (M-CSF,
Peprotech) at 100 ng/mL. The protocol was approved by the Scientific Committee of Institut de Recerca
de la Sida – IrsiCaixa and the Ethics Review Board of Hospital Germans Trias i Pujol. Buffy coats
were purchased from the Catalan Banc de Sang i Teixits (http://www.bancsang.net/en/index.html).
The buffy coats received were totally anonymous and untraceable and the only information given was
whether or not they have been tested for disease. All donors provided informed consent at the time of
blood extraction.
The human cell lines HEK293-T, TZM-bl (AIDS Reagent Program, National Institutes of Health,
Bethesda, MD) MDA-MB-468 (ATCC® HTB132™) and T47D (ATCC® HTB-133™) (American Type
Culture Collection, ATCC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Madrid, Spain) supplemented with 10% heat inactivated FCS, 100 U/mL penicillin, and 100 ug/mL
streptomycin. SAMHD1 knock-out TZM cells were generated by CRISPR/Cas9 technique as described
elsewhere (22).
4.2. Drugs
33-Azido-3-deoxythymidine (zidovudine, AZT), nevirapine (NVP), 1-beta-D-
Arabinofuranosylcytosine (AraC), 9-beta-D-Arabinofuranosyl-2-fluoroadenine (fludarabine), 2-Amino-
9-beta-D-arabinofuranosyl-6-methoxy-9H-purine (nelarabine), 2-Chloro-2′-deoxyadenosine
(cladribine), 2-chloro-9-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (clofarabine), 2′,2′-
Difluorodeoxycytidine (gemcitabine), 5-Fluoro-2-desoxyuridine (floxuridine), 5-Fluoropyrimidine-
2,4-dione (fluorouracil), pemetrexed and 4′-N-benzoylstaurosporine (midostaurin) were purchased
from Sigma-Aldrich (Madrid, Spain). Palbociclib, ribociclib and abemaciclib were purchased from
Selleckchem (Munich, Germany). 4-amino-10-methylfolic acid (methotrexate) was purchased from
Eurodiagnosticos SL (Madrid, Spain).
4.3. Virus
Envelope-deficient HIV-1 NL4-3 clone encoding IRES-GFP (NL4-3-GFP) was pseudotyped with
VSV-G by cotransfection of HEK293T cells using polyethylenimine (Polysciences, Warrington, PA,
USA) as previously described [44]. For the production of viral-like particles carrying Vpx (VLP-Vpx),
HEK293T cells were cotransfected with pSIV3+ and a VSV-G expressing plasmid. Three days after
transfection, supernatants were harvested, filtered and stored at −80 ◦C. Viral stocks were concentrated
using Lenti-X concentrator (Clontech, Mountain View, CA, USA). Viruses were titrated by infection of
TZM cells followed by GFP quantification by flow cytometry.
4.4. Virus Infections
MDMs were pretreated with VLP-Vpx for 4h before infection or left with fresh media as a control.
Cells were then infected with VSV-pseudotyped NL4-3-GFP and drugs were added at the time of
infection. Viral replication was measured two days later by flow cytometry, as well as measurement of
the viability of cells by gating live vs. dead cells. The anti-HIV activity of the different compounds
was determined by infection of cells in the presence of different concentrations of the drug and 50%
effective concentrations (EC50) were calculated, as previously described [23].
Cancers 2020, 12, 713 15 of 19
4.5. Western Blot
Cell extracts were prepared for Western blot protein analysis as described before [22]. Briefly, cells
were rinsed in ice-cold phosphate-buffered saline (PBS) and extracts prepared in lysis buffer (50 mM
Tris HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 10 mM Na β-glycerophosphate,
50 mM NaF, 5 mM Na Pyrophosphate, 270 mM sucrose and 1% Triton X-100) supplemented
with protease inhibitor (Roche, Basel, Switzerland) and 1 mM phenylmethylsulfonyl fluoride.
Lysates were subjected to SDS-PAGE and transferred to a PVDF membrane (ImmunolonP, Thermo,
Waltham, MA, USA). The following antibodies were used for immunoblotting: anti-rabbit and
anti-mouse horseradish peroxidase-conjugated secondary antibodies (1:5000; Pierce, Waltham, MA,
USA; anti-human Hsp90 (BD Biosciences, Franklin Lakes, NJ, USA; 610418), anti-SAMHD1 (1:2500;
ab67820, Abcam, Cambridge, UK) and anti-RRM2 (1:1000; ab115701, Abcam) and anti-phospho-CDK2
(Thr160; 2561), anti-CDK2 (2546), anti-CDK1 (77055) anti-Rb (9309) anti-phospho-Rb (Ser807/811,
9308) anti-E2F1 (3742), anti-phospho-SAMHD1 Thr592 (15038) (all 1:1000; Cell Signaling Technologies,
Danvers, MA, USA).
4.6. Evaluation of Cytotoxicity
Cytotoxicity measurements in cell lines were based on the viability of cells that had been treated
or not with various concentrations of the different anticancer compounds. Cells were treated at the
indicated doses of the test compounds for 3 days and the number of viable cells was quantified by a
tetrazolium-based colorimetric method (MTT method) as described elsewhere [23]. The MTT assay
measured the metabolic activity of cells, resulting in a very sensitive procedure to evaluate cell viability
and cell proliferation, including the effect of cytostatic agents that slow or stop cell growth.
4.7. Evaluation of Drug Combination
Drug combinations were evaluated using the combination index (CI)-isobologram equation, a
method widely used in pharmacology to study drug interactions. Relative values of drug activity
were used to calculate CI as implemented in the Compusyn software (Combosyn Inc., Paramus, NJ,
USA) [45]. In brief, combination experiments were performed by using serial dilutions of each drug
alone or a mixture of the two drugs evaluated, as recommended by the Chou–Talay method using a
non-constant ratio combination [46]. CI was calculated for all combinations and those combinations,
including concentrations of SAMHD1-activating drugs around calculated IC50, were considered for
quantification of drug combination effect. Drug combinations with CI < 1 were considered synergic [46].
4.8. Immunohistochemistry
Tissue sections from lung and pancreas tumor tissues (T2235188-1 and T2235152,
respectively, Amsbio UK), were used to evaluate SAMHD1 expression in tumor tissues ex vivo.
All immunohistochemical analyses were performed in the Histopatology core facility at Germans Trias i
Pujol Research Institute. A polyclonal rabbit anti-SAMHD1 antibody (cat. no. 12586-1-AP, Proteintech,
Rosemont, IL, USA) and an automated detection system were utilized. The specificity of the polyclonal
antibody was previously tested by Western blot analysis in cell lines and by immunohistochemistry
using paraffin-embedded normal tissue. Images were obtained in a Zeiss Axioskop 2 microscope using
ZEN blue 2011 software.
4.9. Statistical Methods
Data were analyzed with the PRISM statistical package. If not stated otherwise, all data were
normally distributed and expressed as mean ± SD. p-values were calculated using an unpaired,
two-tailed, t-student test.
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5. Conclusions
Our results confirm and expand the number of drugs whose efficacy might be affected by
SAMHD1 function, demonstrating the importance of SAMHD1 for targeted health therapies including
nucleoside analogues such as treatments for cancer and viral infections. Moreover, we show that
pharmacological modulation of SAMHD1 can significantly enhance current antimetabolite-based
anticancer therapies. Nucleobase and nucleoside analogues are an important class of anti-cancer
and antiviral drugs. Thus, understanding the clinical and molecular determinants of drug efficacy is
paramount to improve the efficacy of anticancer treatment. Based on our findings, the development
of robust SAMHD1 inhibitors and activators that can potentiate antimetabolite therapeutic regimens
should become a priority.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/3/713/s1,
Figure S1: Efficacy of the multi-kinase inhibitor midostaurin depends on SAMHD1 expression, Figure S2: Relative
effect of the combination of palbociclib-fluorouracil and midostaurin-palbociclib, Figure S3: Expression of cell
cycle proteins and SAMHD1 in the cell lines used, Table S1: Cytotoxic activity of evaluated drugs in the different
cell lines.
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